Evidence map›Paper›PMID 39185348›Full record

ReviewInternational journal of nanomedicine2024

Emerging Trends in the Application of Extracellular Vesicles as Novel Oral Delivery Vehicles for Therapeutics in Inflammatory Diseases.

Mingtang Zeng, Maozhu Liu, Xuelin Tao, Xi Yin, Chao Shen, Xueyan Wang

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Therapeutic Potential of Extracellular Vesicles in Oral Inflammation.International journal of molecular sciences · 2025
    Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mingtang Zeng *Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Maozhu Liu *Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Xuelin Tao *Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Xi YinDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Chao ShenDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Xueyan WangDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation involves complex immune responses where cytokines such as TNF-α, IL-1, and IL-6 promote vasodilation and increased vascular permeability to facilitate immune cell migration to inflammation sites. Persistent inflammation is linked to diseases like cancer, arthritis, and neurodegenerative disorders. Although oral anti-inflammatory drugs are favored for their non-invasiveness and cost-effectiveness, their efficacy is often compromised due to gastrointestinal degradation and limited bioavailability. Recent advancements highlight the potential of extracellular vesicles (EVs) as nanocarriers that enhance drug delivery by encapsulating therapeutic agents, ensuring targeted release and reduced toxicity. These EVs, derived from dietary sources and cell cultures, exhibit excellent biocompatibility and stability, presenting a novel approach in anti-inflammatory therapies. This review discusses the classification and advantages of orally administered EVs (O-EVs), their mechanism of action, and their emerging role in treating inflammatory conditions, positioning them as promising vectors in the development of innovative anti-inflammatory drug delivery systems.

Indexed as

Anti-Inflammatory AgentsExtracellular VesiclesInflammationAdministration, OralAnimalsDrug CarriersDrug Delivery SystemsHumansAnti-Inflammatory AgentsDrug Carriersanti-inflammatorydrug delivery systemsextracellular vesiclesfoodoral administration

Identifiers

PMID39185348
PMCPMC11345024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.